Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00716534. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin/Paclitaxel in Combination With ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
Study identification
- NCT ID
- NCT00716534
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 145 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2008 (Type not available)
- Primary completion
- Apr 2012 (Actual)
- Completion
- Apr 2012 (Actual)
- Last update posted
- Apr 29, 2013
2008 – 2012
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 15850 | Chandler | Arizona | 85224 | — |
| Site Reference ID/Investigator# 15846 | Peoria | Arizona | 85381 | — |
| Site Reference ID/Investigator# 15841 | Miami | Florida | 33136 | — |
| Site Reference ID/Investigator# 7179 | Atlanta | Georgia | 30322 | — |
| Site Reference ID/Investigator# 15851 | Lansing | Michigan | 48912 | — |
| Site Reference ID/Investigator# 15844 | Lebanon | New Hampshire | 03756 | — |
| Site Reference ID/Investigator# 22443 | Hackensack | New Jersey | 07601 | — |
| Site Reference ID/Investigator# 15848 | Greensboro | North Carolina | 27403 | — |
| Site Reference ID/Investigator# 22444 | Canton | Ohio | 44718 | — |
| Site Reference ID/Investigator# 15847 | Cleveland | Ohio | 44195 | — |
| Site Reference ID/Investigator# 26842 | Hershey | Pennsylvania | 17033-0850 | — |
| Site Reference ID/Investigator# 13101 | Philadelphia | Pennsylvania | 19106 | — |
| Site Reference ID/Investigator# 24122 | Philadelphia | Pennsylvania | 19107 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00716534, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2013 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00716534 live on ClinicalTrials.gov.